Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM
Hemogenyx Pharmaceuticals has announced the posting of its Annual Report and Accounts for the year ending 31 December 2023. The report, along with the Notice of the Annual General Meeting (AGM) and a Form of Proxy, is now available on the company's website. The AGM will take place on 27 June 2024 at 2:00 pm BST at SP Angel Corporate Finance LLP's offices in London. Hemogenyx Pharmaceuticals focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative power of bone marrow transplants.
Shareholders can find more details on the company's investor relations page. The company has its headquarters in London and operates subsidiaries in New York City. The announcement is distributed by RNS, a news service of the London Stock Exchange, and is compliant with regulations established by the Financial Conduct Authority.
- Annual Report and Accounts for the year ended 31 December 2023 have been posted, ensuring transparency and regulatory compliance.
- Notice of AGM and Form of Proxy available, facilitating shareholder involvement.
- AGM scheduled for 27 June 2024, providing a platform for shareholder engagement and corporate governance.
- Hemogenyx Pharmaceuticals focuses on developing treatments for blood and autoimmune diseases, which could attract investor interest.
- Company’s research facility located in NYC, highlighting a strong operational base.
- No financial data or performance metrics were disclosed in the press release, leaving investors without important information on the company’s progress.
- Absence of updates on clinical trials or product development, which could be a negative indicator for stakeholders focused on pipeline progress.
- No mention of revenue, profits, or losses, potentially indicating a lack of significant financial achievements or progress.
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Posting of Annual Report & Notice of Annual General Meeting
LONDON, UNITED KINGDOM / ACCESSWIRE / June 3, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2023, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and are available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 27 June 2024 at 2.00 pm BST at the offices of SP Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, London W1S 2PP.
Enquiries:
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
Peter Redmond, Director | peter.redmond@hemogenyx.com |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is the significance of Hemogenyx Pharmaceuticals' Annual Report posted on 3 June 2024?
When and where is the Hemogenyx Pharmaceuticals AGM scheduled?
Where can shareholders access Hemogenyx Pharmaceuticals' Annual Report and AGM details?
What focus areas does Hemogenyx Pharmaceuticals specialize in?
Why is the AGM important for Hemogenyx Pharmaceuticals shareholders?
